ClinicalTrials.Veeva

Menu

IMRT Versus 3DCRT for Locally Advanced Rectal Cancer, Prospective Phase II Study.

Clalit Health Services logo

Clalit Health Services

Status

Completed

Conditions

Toxicity Due to Radiotherapy
Radiotherapy
Rectal Cancer

Treatments

Radiation: Intensive Modulated Radiation Therapy
Radiation: 3-Dimension Conformal Radiation Therapy

Study type

Interventional

Funder types

Other

Identifiers

NCT06160570
IMRT versus 3D to rectum

Details and patient eligibility

About

The goal of this prospective phase II study was to determine whether personalized planning-based nCRT for LARC would indeed decrease small bowel dose, and whether selected plans, specifically prioritizing lower dose to small bowel, would result in lower rates of acute GI toxicity compared with previously reported rates.

Full description

The standard of care for locally advanced rectal cancer is neoadjuvant chemoradiotherapy. However, acute gastrointestinal (GI) toxicity is common. Some retrospective studies suggested that Intensity Modulated Radiation Therapy( IMRT) reduces acute bowel toxicity compere to 3D conformal radiotherapy (3DCRT).The aim of this prospective phase II study to determine whether the use of IMRT planning in neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer can decrease small bowel irradiation dose compared to commonly used 3D conformal techniques ,and the rate of acute GI toxicity.

Patients (pts) with clinical stage II-III rectal adenocarcinoma were enrolled in a prospective phase II study of preoperative chemoradiation. For each patient two radiation plans were performed: IMRT and 3DCRT. After comparing two DVH (dose volume histogram) plans for organs at risk (OARs), such as small bowel and bladder, pts were treated according to the plan with maximal critical organs sparing. All Patients received 45 Gy in 25 fractions to the rectum and draining lymph nodes, followed by boost to the tumor, with concurrent capecitabine or 5- Fluorouracil .Weekly follow up was performed to assess acute toxicity.

The investigators hypothesize that the use of IMRT in neoadjuvant chemoradiation for locally advanced rectal cancer may reduce the small bowel and bladder irradiated volume and consequently reduce acute toxicity.

Enrollment

75 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with locally advanced rectal adenocarcinoma
  • Performance status of 0-2
  • Adequate hematologic, renal, and hepatic function

Exclusion criteria

  • Prior radiotherapy to pelvis
  • Metastatic disease at diagnosis

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

75 participants in 2 patient groups

IMRT
Active Comparator group
Description:
Intensive Modulated Radiation Therapy
Treatment:
Radiation: Intensive Modulated Radiation Therapy
3DCRT
Active Comparator group
Description:
3-Dimension Conformal Radiation Therapy
Treatment:
Radiation: 3-Dimension Conformal Radiation Therapy

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems